Bristol Myers Squibb (BMY)

[DewDiligence]

Opdivo/Yervoy combo not statsig better than Opdivo monotherapy on (co-primary) RFS* endpoint in adjuvant melanoma for PD-L1<1% subgroup:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-checkmate-115800584.html

The trial remains blinded and will continue in order to evaluate RFS in the entire patient pool, which is also a co-primary endpoint.

It’s curious that the subgroup analysis had enough events for statistical evaluation before the full patient pool did. (This usually works the other way.)

*Essentially the same as PFS.